Q-omics provides the consensus-scored RNF25 profile across patient tissues and cancer cell-line models. RNF25 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RNF25 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, RNF25 RNA expression shows 18,865 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KICH as cancer lineages where RNF25 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNF25 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNF25 survival associations across molecular data types. RNF25 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNF25 RNA expression–survival associations across cancer types. High RNF25 expression shows unfavorable associations in ACC, UVM, LIHC, LGG, SKCM and UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RNF25 RNA expression.
This table summarizes RNF25 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in KICH for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RNF25. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNF25 shows lower tumor expression in KICH and higher tumor expression in HNSC, LIHC, COAD, CHOL and STAD. The KICH box plot shows higher RNF25 RNA expression in normal versus tumor tissue (log2 FC = −1.634, t-test p < 0.001).
This table shows molecular features associated with RNF25 in patient tissues and cancer cell lines. In patient samples, RNF25 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RNF25 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
